Switching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit?

E-ISSN： 1365-2516|21|3|297-299

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.3, 2015-05, pp. : 297-299

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Allergic reaction in a cohort of haemophilia A patients using plasma‐derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII

HAEMOPHILIA, Vol. 21, Iss. 4, 2015-07 ,pp. : e281-e285

John Wiley & Sons Inc

Access to resources Recommend Favorite

Longer‐acting clotting factor concentrates for hemophilia

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S167-S175

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 300-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Gringeri et al.: ‘recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling’

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : e489-e492

John Wiley & Sons Inc

Access to resources Recommend Favorite

Kogenate^®® FS: antihemophilic factor rFVIII-FS

By Lusher Jeanne Chitlur Meera

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 699-708

Future Medicine

Access to resources Recommend Favorite